

February 1, 2021

|                                                                                                                                                                                                          |                                                                                                                                                                                                      |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| To<br>Listing Department,<br><b>NATIONAL STOCK EXCHANGE OF INDIA LIMITED</b><br>Exchange Plaza,<br>Bandra Kurla Complex, Bandra (E),<br><b>MUMBAI -400 051</b><br><br><b>Company Code No. AUROPHARMA</b> | To<br>The Corporate Relations Department<br><b>BSE LIMITED</b><br>Phiroz Jeejeebhoy Towers,<br>25 <sup>th</sup> floor, Dalal Street,<br><b>MUMBAI -400 001</b><br><br><b>Company Code No. 524804</b> |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

Dear Sir,

**Sub: Intimation of Board Meeting.**

We hereby inform pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, that a Meeting of the Board of Directors of the Company will be held on **Wednesday, 10<sup>th</sup> February 2021** to consider and approve inter alia, the following:

1. Standalone & Consolidated Unaudited Financial Results of the Company for the third quarter and nine months period ended December 31, 2020 and
2. Payment of Third Interim Dividend, if any, for the financial year 2020-21.

Further to our letter dated December 29, 2020 informing the closure of Trading Window of the Company from January 1, 2021 until 48 hours from the date of declaration of the Unaudited Financial Results of the Company for the third quarter and nine months period ended December 31, 2020, we inform you that the Trading Window will remain closed up to February 12, 2021 and shall be re-opened on February 13, 2021.

Please take the information on record.

Thanking you,

Yours faithfully,  
For **AUROBINDO PHARMA LIMITED**

  
B. Adi Reddy  
Company Secretary

